Total Payments
$152,799
2024 Payments
$5,862
Companies
14
Transactions
136
Medicare Patients
212
Medicare Billing
$18,649
Payment Breakdown by Category
Research$140,098 (91.7%)
Travel$8,507 (5.6%)
Food & Beverage$2,799 (1.8%)
Consulting$1,375 (0.9%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $140,098 | 57 | 91.7% |
| Travel and Lodging | $8,507 | 34 | 5.6% |
| Food and Beverage | $2,799 | 42 | 1.8% |
| Consulting Fee | $1,375 | 2 | 0.9% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$140,098
57 transactions
General
$12,701
79 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $125,067 | 6 | $0 (2022) |
| PFIZER INC. | $5,883 | 8 | $0 (2023) |
| Eli Lilly and Company | $4,446 | 11 | $0 (2023) |
| SANOFI PASTEUR INC. | $3,929 | 25 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $3,594 | 21 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,629 | 11 | $0 (2022) |
| AstraZeneca UK Limited | $2,271 | 17 | $0 (2018) |
| GlaxoSmithKline, LLC. | $1,461 | 7 | $0 (2017) |
| Boehringer Ingelheim International GmbH | $1,336 | 11 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $737.99 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,862 | 34 | SANOFI PASTEUR INC. ($3,929) |
| 2023 | $7,186 | 21 | PFIZER INC. ($4,613) |
| 2022 | $128,044 | 14 | Valneva Austria GmbH ($125,067) |
| 2021 | $2,447 | 9 | Eli Lilly and Company ($2,401) |
| 2020 | $1,405 | 10 | Eli Lilly and Company ($717.21) |
| 2019 | $1,250 | 5 | PFIZER INC. ($1,250) |
| 2018 | $3,440 | 23 | AstraZeneca UK Limited ($1,766) |
| 2017 | $3,166 | 20 | GlaxoSmithKline, LLC. ($1,461) |
All Payment Transactions
136 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $49.60 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $40.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $40.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $475.26 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $277.96 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $152.41 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $108.54 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $80.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $371.74 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $151.97 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $130.00 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 04/04/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $105.00 | General |
| 04/04/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $82.86 | General |
| 04/03/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $839.17 | General |
| 04/03/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $151.97 | General |
| 04/03/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 02/29/2024 | SANOFI PASTEUR INC. | — | — | Cash or cash equivalent | $56.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/29/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $18.54 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $100.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $53.00 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $41.68 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
| 02/28/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $16.04 | Research |
| Study: A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $125,067 | 6 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $4,613 | 2 |
| A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | SANOFI PASTEUR INC. | $2,627 | 16 |
| A Phase IIb, 24 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once daily via a dry powder inhaler, versus placebo, in participants with asthma | GlaxoSmithKline, LLC. | $1,461 | 7 |
| A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | SANOFI PASTEUR INC. | $1,302 | 9 |
| A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN | Eli Lilly and Company | $1,200 | 2 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $1,073 | 2 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $635.91 | 2 |
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $581.52 | 6 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $555.00 | 1 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $513.00 | 1 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $272.68 | 1 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $196.70 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 59 | 65 | $13,044 | $2,791 |
| 2022 | 2 | 58 | 62 | $13,386 | $3,020 |
| 2021 | 3 | 57 | 61 | $29,260 | $11,098 |
| 2020 | 2 | 38 | 39 | $10,693 | $1,740 |
Total Patients
212
Total Services
227
Medicare Billing
$18,649
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 49 | $12,824 | $2,755 | 21.5% |
| 81003 | Automated urinalysis test | Office | 2023 | 16 | 16 | $219.77 | $35.20 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 47 | 51 | $13,165 | $2,996 | 22.8% |
| 81003 | Automated urinalysis test | Office | 2022 | 11 | 11 | $220.44 | $24.37 | 11.1% |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | Office | 2021 | 21 | 21 | $18,900 | $8,994 | 47.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 29 | $7,511 | $1,559 | 20.8% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 11 | 11 | $2,849 | $544.45 | 19.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 26 | $7,678 | $1,091 | 14.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 13 | $3,014 | $649.50 | 21.5% |
About Dr. Cory Anderson, MD
Dr. Cory Anderson, MD is a Family Medicine healthcare provider based in Mesa, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720050727.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cory Anderson, MD has received a total of $152,799 in payments from pharmaceutical and medical device companies, with $5,862 received in 2024. These payments were reported across 136 transactions from 14 companies. The most common payment nature is "" ($140,098).
As a Medicare-enrolled provider, Anderson has provided services to 212 Medicare beneficiaries, totaling 227 services with total Medicare billing of $18,649. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Mesa, AZ
- Active Since 02/03/2006
- Last Updated 12/29/2011
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1720050727
Products in Payments
- NURTEC ODT (Drug) $4,613
- VERAMYST (Drug) $1,461
- MK-7264 (Drug) $1,404
- BEVESPI AEROSPHERE (Drug) $1,123
- PNEUMOVAX 23 (Biological) $150.00
- Proclaim IPG (Device) $25.73
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Mesa
Terry O'reilly, M.d, M.D
Family Medicine — Payments: $586,349
Family Medicine $586,349
Suzanne Bentz, Do, DO
Family Medicine — Payments: $165,113
Family Medicine $165,113
Donna Desantis, Md, MD
Family Medicine — Payments: $76,940
Family Medicine $76,940
Yadwinder Dhillon, M.d, M.D
Family Medicine — Payments: $51,311
Family Medicine $51,311
Dr. Karen Acevedo-Mogharbel, D.o, D.O
Family Medicine — Payments: $46,281
Family Medicine $46,281
James Gunn, M.d, M.D
Family Medicine — Payments: $17,717
Family Medicine $17,717